European Pharmaceutical Review

JULY 21, 2023

Manufacturers must navigate this complex landscape, obtain necessary certifications, and stay updated with evolving regulations. Hayat Biotech’s global supply chain, spanning distribution to 64 countries, entails the involvement of multiple suppliers, distributors, and contract manufacturing organisations.

Vaccines 94

Vaccines FDA Communication Hospitals 94

pharmaphorum

NOVEMBER 19, 2020

Amid the turmoil and the race to not only find a vaccine but also help to care for those who are battling the long-term effects of COVID-19, healthcare organisations need to sharpen their communication skills. Creating a more informed patient can improve outcomes and ultimately, quality of life. Patient focus.

Communication 76

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 76

Pharmaceutical Technology

APRIL 5, 2023

More than a decade after the first patient was treated with a CAR-T therapy, six therapies relying on the same principles have been approved by the US Food and Drug Administration (FDA) and marketed to thousands of patients. How can we better educate the patients? This interview has been edited for clarity and length.

FDA 59

FDA Immunization 59

pharmaphorum

MARCH 10, 2022

Tapping into the momentum of biologics requires investment but identifying the right areas to invest in is a challenge in an evolving market. However, producing generic treatments is significantly different to developing synthesised small-molecule drugs, pushing companies like Chiesi to re-evaluate their role in drug production.

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunization 97

pharmaphorum

JUNE 20, 2022

“We have a lot of data about pharmaceutical pipelines, sales in the market, and, crucially, about the forecasts and how the market might evolve, which is all derived from sell-side equity analysts,” Verdin states. If you have a pipeline, you hope to see a return, and there are patients at the end of this who do see a benefit.”

FDA 52

FDA 52

European Pharmaceutical Review

DECEMBER 21, 2022

Sponsors must understand this rapidly changing regulatory landscape and be able to pivot quickly to optimise their clinical trial strategies. For example, the MHRA launched its Innovative Licensing and Access Pathway (ILAP) in January 2021 with the goal “…to accelerate the time to market, facilitating patient access to medicines.

Compounding 107

Compounding Controlled Substances FDA Patient Care 107

pharmaphorum

FEBRUARY 1, 2022

With limited physical access to labs and patients, the influx of updated technology was a welcome change. This is hardly surprising, given that the NHS in the UK is one of the few organisations still using fax machines and pagers to conduct daily activities. this is not always a straightforward process.

52

52

European Pharmaceutical Review

JUNE 16, 2023

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines. What are the current three main challenges in clinical trials?

Communication 101

Communication Pharmaceutical Companies Pharmaceutical Companies Patient Care 101

European Pharmaceutical Review

OCTOBER 2, 2023

It provides unparalleled opportunities to source valuable partnerships, secure contracts, and stay ahead in a rapidly evolving industry. Commitment to sustainability and social responsibility CPHI Barcelona is committed to organising an environmentally and socially responsible event.

Packaging 97

Packaging 97

European Pharmaceutical Review

APRIL 30, 2024

Vikas Gupta (VG): In the years preceding the Covid pandemic, the ATMP s market, including both the innovators as well as the contract development and manufacturing organisations (CDMOs), was a bit too optimistic about its growth prospects as it was building significant manufacturing capacity focusing primarily on viral vectors.

Vaccines 78

Vaccines FDA 78

pharmaphorum

MAY 18, 2022

Health data research in the UK is rapidly evolving, with new capabilities emerging through the rise of hybrid engagement and the accelerated adoption of digital technologies. However, expanding that model to cover all data in all disease areas is a monumental and highly ambitious task.

Hospitals 78

Hospitals 78

European Pharmaceutical Review

FEBRUARY 12, 2024

‘From bench to bedside’ is a well-known aphorism that merely hints at the arduous journey drug treatments must undergo from their position as a candidate molecule or soon to be explored pathway, to becoming a tablet, injection, or infusion administered to patients worldwide. How does it do this?

Process Improvement 88

Process Improvement Packaging 88

pharmaphorum

OCTOBER 6, 2020

But for many life sciences organisations, these tools are either not yet fully adopted or are not being put to good use within their regulatory functions. Adopting intelligent automation could help organisations realise disruptive benefits that are above and beyond the tangible gains of cost, quality and productivity improvements.

Documentation 103

Documentation Communication Labelling Data Entry 103

European Pharmaceutical Review

OCTOBER 12, 2023

With the goal of supplying cell therapies, vaccines and other essential medicines such as antibody drugs to patients, the facilities aim to address major supply challenges and navigate the intricacies of producing fragile biological products. Meath opened last month. The new £26.4 The new £26.4

Vaccines 84

Vaccines Dosage Pharmaceutical Companies Pharmaceutical Companies 84

pharmaphorum

SEPTEMBER 2, 2022

The healthcare industry is evolving rapidly, with data and digital technologies transforming everyday communications as we know them. This disruption has changed the way doctors and cancer patients expect to experience services and products, and there is no going back now. The digital age is here to stay. About the author.

Communication 59

Communication Pharmaceutical Companies Pharmaceutical Companies Customer Service 59

pharmaphorum

MAY 24, 2021

The marketing content mix for pharma is evolving and pharma marketers are eager to find ways to produce more content, quickly, while reducing inefficiencies and generating savings,” explains Robb. It can be used for sales, marketing and patient communication materials, in print or digital form.

Communication 89

Communication Packaging Pharmaceutical Companies Pharmaceutical Companies 89

pharmaphorum

JUNE 14, 2022

The investment flowing into the sector is not limited to just the development of medicines, there has also been a focus on rapidly developing capability and capacity to manufacture both traditional pharmaceuticals and biologic medicines. Evolving regulatory landscape.

FDA 97

FDA Vaccines 97

Pharmaceutical Technology

JUNE 20, 2023

The current tech landscape is rapidly evolving, with advancements in areas such as big data and conversational platforms. Consent documents often describe technical medical conditions and regulatory bodies are increasing pressure on sponsors to ensure that patient-facing information can be easily understood by patients.

Medical Records 52

Medical Records Documentation Communication Dosage 52

Pharmaceutical Technology

FEBRUARY 20, 2023

He says these issues must be urgently addressed over the next few years as advancing medical knowledge and the role of genomics in treating disease ushers in a new era of precision medicine and new potential to address diseases that affect certain populations. Can you tell us a little bit about Viroclinics-DDL?

Vaccines 52

Vaccines Communication Immunization 52

Pharmaceutical Technology

MAY 9, 2023

The clinical trials landscape is evolving more rapidly than ever before. The Covid-19 pandemic catalysed an enormous upswing in the adoption of innovations including telemedicine, wearables and remote patient monitoring. The COVID-19 pandemic and geopolitical instability have put new pressures on the pharmaceutical supply chain.

Vaccines 52

Vaccines Process Improvement Communication 52